Clinical Trial Update: The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder [Phase 4]

View source ↗

Summary

Phase 4 trial completed evaluating a weight-gain agent for treating olanzapine-associated weight gain in patients with schizophrenia, schizophreniform disorder,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• Weight-Gain Agent
• olanzapine (olanzapine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenia, Psychotic Disorders | Phase 4 | Status: COMPLETED